[Esaprazole vs sulglicotide in the treatment of dyspeptic patients with chronic superficial gastritis of the antrum].
Fifty dyspeptic patients with histologically proven chronic superficial antral gastritis were treated for 6 weeks, in a randomized single-blind study, with esaprazole (450 mg bid) or sulglicotide (200 mg tid). Both drugs significantly improved the symptomatic score after 3 and 6 weeks (p less than 0.01), and the percentual rate of improvement was similar in the two groups studied. Similarly, both treatments significantly reduced the inflammation of gastric mucosa. Drugs were ineffective in clearing Helicobacter pylori from the antral mucosa (as assessed by the urease test, performed at entry and after 6 weeks). No side effects occurred after esaprazole or sulglicotide administration. The results of the present study suggest that esaprazole, a new gastroprotective drug, may have a role in the therapy of dyspeptic patients with chronic superficial gastritis.
Sabbatini
F
F
II Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli.
Minieri
M
M
Castiglione
F
F
Di Lanno
E
E
Mazzacca
G
G
D000293:Adolescent; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004415:Dyspepsia / Q000188:drug therapy*; D005260:Female; D005756:Gastritis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011706:Pyloric Antrum; D012795:Sialoglycoproteins / Q000627:therapeutic use*; D016037:Single-Blind Method
D000897:Anti-Ulcer Agents; D010879:Piperazines; D012795:Sialoglycoproteins; C009354:sulglicotide; C042123:esaprazole
Esaprazolo vs sulglicotide nel trattamento di pazienti dispeptici portatori di gastrite cronica superficiale dell'antro.